Spikevax – Talk Bio

Vinay Prasad Details New Approach to COVID-19 Vaccine Approvals in Recent FDA Memos

1 week ago talkbio0Tagged Child, COVID19 (disease), Evidence, Prasad, regulatory decisions, risk-benefit analysis, Spikevax, United States Food and Drug Administration, vaccine approval, Vaccine Safety, Vaccines, Vinay

Vinay Prasad; COVID-19 vaccine; FDA; vaccine approval; children; Spikevax; regulatory decisions; vaccine safety; evidence; risk-benefit analysis

Moderna’s COVID Vaccine Wins FDA Approval for At-Risk Young Children

2 months ago talkbio0Tagged Approved, At-Risk, Child, conditions, Covid Vaccine, Moderna, Spikevax, United States Food and Drug Administration

Moderna; FDA approval; COVID vaccine; children; at-risk; Spikevax; underlying conditions; full approval

FDA Approves Moderna’s Next-Generation Covid Vaccine With Limited Use for Most Healthy People

3 months ago talkbio0Tagged Approved, COVID19 (disease), Elderly (population group), high-risk, Moderna, next-generation Covid vaccine, Omicron, Omicron JN.1, restrictions, Spikevax, United States Food and Drug Administration, Vaccines, Variant

Moderna; FDA approval; mNexspike; next-generation Covid vaccine; vaccine restrictions; Covid-19; Spikevax; elderly; high-risk medical conditions; Omicron JN.1 variant

Moderna Faces Second Consecutive Marketing Breach for Spikevax Vaccine

12 months ago talkbio0Tagged Biomechanical compliance, COVID19 (disease), Marketing Breach, Moderna, regulatory, Spikevax, Vaccines

Moderna, Spikevax, Marketing Breach, COVID-19 Vaccine, Regulatory Compliance

FDA Approves Moderna’s RSV Vaccine, Marking Its Second Commercial Product

1 year ago talkbio0Tagged Approved, COVID19 (disease), Moderna, mRESVIA, Respiratory syncytial virus, RNA, Messenger, Spikevax, United States Food and Drug Administration, Vaccines

Moderna, RSV Vaccine, FDA Approval, mRNA Technology, Respiratory Syncytial Virus, COVID-19, Spikevax, mRESVIA